Gastroretentive Drug Delivery Systems Market Size Worth $19.7 Billion By 2028

Grand View Research, Inc.

SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- The global gastroretentive drug delivery systems market size is estimated to reach USD 19.7 billion by 2028, registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently. Hence enhancing absolute bioavailability and maximizing its absorption is expected to boost market growth during the forecast period.

Key suggestions from the report:

• The floating drug delivery systems held the largest market share in 2020
• These systems have a lower density than gastric fluids and hence stay buoyant in the stomach without altering the gastric emptying rate for a long time
• The liquid dosage form segment is expected to grow at the fastest rate during the forecast period due to the availability of a wide range of liquid-based gastroretentive products in treating all types of gastric disorders
• The online pharmacies segment is predicted to witness the fastest growth rate over the forecast timeframe as they offer a wide range of options along with in-depth drug information
• North America held the largest market share and is anticipated to maintain its dominance over the forecast period
• This is attributable to the growing prevalence of H. Pylori infection, increasing R&D expenditure, and rising technological advancements in gastroretentive DDSs.

Read 150 page research report with ToC on "Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Tablets, Liquid, Capsule), By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028" at: https://www.grandviewresearch.com/industry-analysis/gastroretentive-drug-delivery-systems-market

Several advantages of these DDSs include curative efficiency and an increase in the bioavailability of drugs. The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site. It also offers higher efficiency owing to reduced counter activity by the body. Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.